References
- Auboeuf, D., J. Rieusset, L. Fajas, P. Vallier, V. Frering, J. P Riou, B. Staels, J. Auwerx, M. Laville and H. Vidal. 1997. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319-1327 https://doi.org/10.2337/diabetes.46.8.1319
- Bouchard, C. 1995. Genetics and the metabolic syndrome. Int. J. Obes. 19(Suppl. 1), S52-S59
- Chinetti, G., F. G. Gbaguidi, S. Griglio, Z. Mallat, M. Antonucci, P. Poulain, J. Chapman, J. C. Fruchart, A. Tedgui, J. Najib-Fruchart and B. Staels. 2000. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator- activated receptors. Circulation 101, 2411-2417 https://doi.org/10.1161/01.CIR.101.20.2411
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection. 2001. Evaluation and treament of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486-2497 https://doi.org/10.1001/jama.285.19.2486
- Flavell, D. M., T. I. Pineda, Y. Jamshidi, D. Evans, J. R. Diamond, R. S. Elkele, S. R. Bujac, G. Miller, P. J. Talmud, B. Stales and S. E. Humphries. 2000. Variation in the PPAR alpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologica 43, 673-680 https://doi.org/10.1007/s001250051357
-
Garenc, C., S. Aubert, J. Laroche, J. Girouard, M. C Vohl, J. Bergeron, F. Rousseau and P. Julien. 2004. Population prevalence of APOE, APOC3 and PPAR-
$\alpha$ mutations associated to hypertriglyceridemia in French Canadians. J. Hum. Genet. 49, 691-700 https://doi.org/10.1007/s10038-004-0208-6 -
Gouni-Berthold, I., E. Giannakidou, D. Muller-Wieland, M. Faust, J. Kotzka, H. K. Berthold and W. Krone. 2004. Association between the PPAR
$\alpha$ L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am. Heart. J. 147, 1117-1124 https://doi.org/10.1016/j.ahj.2003.12.005 - Grundy, S. M., B. Hansen, S. C. Jr. Smith, J. I. Cleeman and R. A. Kahn. 2004. Clinical management of metabolic syndrome: report of the American heart association/national heart, lung, and blood institute/American diabetes Association conference on scientific issues related to management. Circulation 109, 551-556 https://doi.org/10.1161/01.CIR.0000112379.88385.67
- Grundy, S. M. 1999. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 83, 25F-29F https://doi.org/10.1016/S0002-9149(99)00211-8
- Haffner, S. M., R. A. Valdez, H. P. Hazuda, B. D. Mitchell, P. A. Morales and M. P. Stern. 1992. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 41, 715-722 https://doi.org/10.2337/diabetes.41.6.715
- Isseman, I and S. Green. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 https://doi.org/10.1038/347645a0
- Krey, G., O. Braissant, F. L Horset, E. Kalkhoven, M. Perroud, M. G. Parker and W. Wahli. 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator- dependent receptor ligand assay. Mol. Endocrinol. 11, 779-791 https://doi.org/10.1210/me.11.6.779
- Kris-Etherton, P., S. R. Daniels, R. H. Eckel, M. Engler, B. V. Howard, R. M. Krauss, A. H. Lichtenstein, F. Sacks, S. St. Jeor, M. Stampfer, S. M. Grundy, L. J. Appel, T. Byers, H. Campos, G. Cooney, M. A. Denke, E. Kennedy, P. Marckmaaa, T. A. Pearson, G. Riccardi, L. L. Rudel, M. Rudrum, D. T. Stein, R. P. Tracy, V. Ursin, R. A. Vogel, P. L. Zock, T. L. Bazzarre and J. Clark. 2001. AHA scientific statement: summary of the scientific conference on dietary fatty acids and cardiovascular health. Conference summary from the nutrition committee of the American heart association. J. Nutr. 131, 1322-1326
-
Lacquemant, C., F. Lepretre, T. I. Pineda, M. Manraj, G. Charpentie, J. Ruiz, B. Stales and P. Froguel. 2000. Mutation screening of the
$PPAR{\alpha}$ gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab. 26, 393-401 - Lehmann, J. M., J. M Lenhard, B. B. Oliver, G. M. Ringold and S. A. Kliewer. 1997. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410 https://doi.org/10.1074/jbc.272.6.3406
- Mascaro, C., E. Acosta, J. A. Oritz, P. F. Marrero, F. G. Hegardt and D. Haro. 1998. Control of human muscle- type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator activated receptor. J. Biol. Chem. 273, 8560-8563 https://doi.org/10.1074/jbc.273.15.8560
- Osumi, T., J. K. Wen and T. Hashimoto. 1991. Two cis-act ing regulatory sequences in the peroxisome proliferator- responsive enhancer region of rat acyl-CoA oxidase gene. Biochem. Biophys. Res. Commun. 175, 866-871 https://doi.org/10.1016/0006-291X(91)91645-S
- Park, H. S., S. W. Oh, J. H. Kang, Y. W. Park, J. M. Choi, Y. S. Kim, W. H. Choi, H. J. Yoo and Y. S. Kim. 2003. Prevalence and associated factors with metabolic syndrome in South Korea -From the Korean National Health and Nutrition Examination Survey, 1998-. J. Korean Soc. Study Obes. 12, 1-13
- Park, Y. W., S. Zhu, L. Palaniappan, S. Heshka, M. R. Camethon, S. B. Heymsfield. 2003. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third National Health and Nutritional Examination Survey, 1988-1994. Arch. Intern. Med. 163, 427-436 https://doi.org/10.1001/archinte.163.4.427
- Reaven, G. M .1998 Role of insulin resistance in human disease. Diabetes 37, 1595-1607 https://doi.org/10.2337/diabetes.37.12.1595
-
Robitaille, J., C. Brouillette, A. Houde, S. Lemieux, L. Perusse, A Tchernof, D. Gaudet and M. C. Vohl. 2004. Association between the
$PPAR-{\alpha}$ L162V polymorphism and components of the metabolic syndrome. J. Hum. Genet. 49, 482-89 - Schoonjans, K., G. Martin, B. Staels and J. Auwerx. 1997. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8, 159-166 https://doi.org/10.1097/00041433-199706000-00006
- Schoonjans, K., B. Staels and J Auwerx. 1996. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta. 1302, 93-109 https://doi.org/10.1016/0005-2760(96)00066-5
- Schoonjans, K., B. Staels and J. Auwerx. 1996. Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid. Res. 37, 907-925
- Stales, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf and J. C. Fruchart. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088-2093 https://doi.org/10.1161/01.CIR.98.19.2088
- Tai, E. S., S. Demissie, L. A. Cupples, D. Corella, P. W. Wilson, E. J. Schaefer and J. M. Ordovas. 2002. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham offspring study. Arterioscler. Thromb. Vasc. Biol. 22, 805-810 https://doi.org/10.1161/01.ATV.0000012302.11991.42
-
Vohl, M. C., P. Lepage, D. Gaudet, C. Brewer, C. Betard, P. Perron, G. Houde, C. Cellier, J. M. Faith, J. P. Despres, K. Morgan and T. J. Hudson. 2000. Molecular scanning of the human
$PPAR{\alpha}$ gene: association of the L162V mutation with hyperapobetalipoproteinemia. J. Lipid. Res. 41, 945-52 - Western Pacific Regional Office of the World Health Organization. 2000. The International Obesity Task Force: The Asia-Pacific Perspective: redefining obesity and its treatment. Sydney: Health Communications, Australia, http//www.obesityasiapacific.com